Alcimed presentation

Press Release

Total Lab Automation: an opportunity for the in vitro diagnostics industry?

In response to the needs of streamlined processes and increased productivity, the use of Total Lab Automation (TLA) systems is massively increasing in medical biology laboratories. Alcimed, a consulting company specializing in innovation and new businesses, set out to highlight the potential of these workflow automation systems and question the related prospects for actors in vitro diagnostics.

Paediatric drugs, a continuing need

13 December 2018, In December 2006, the European Parliament adopted the Regulation on medicinal products for paediatric use aiming to stimulate pharmaceutical companies to develop medicinal forms intended for children. The European Medicines Agency (EMA) has been noting a significant increase in the number of new paediatric drugs; nevertheless, there is still a genuine need in this area. In fact, today, more than 50% of paediatric prescriptions are for off-label uses. Alcimed, an innovation and new business consulting firm, examined the factors that still limit the development of paediatric drugs, 10 years after the law was introduced.

Emergence of serious games for neurodegenerative diseases Which business models in France?

Although research is constantly moving forward, many neurodegenerative diseases remain poorly understood and grey areas still persist. Consequently, with the low number of effective drug treatments, new disease management methods are being developed. One of these methods is the serious games, alias “serious video games”, which are games developed to have a therapeutic effect. Just imagine if, after a doctor’s appointment, you found video game sessions on your prescription. Alcimed, a consulting company specializing in innovation and new businesses, set out to further explore this trend, which could radically impact current patient care.

How to assess whether a raw material is really becoming critical?

It’s a fact: the French and global industrial sector is heavily depending on many raw materials to ensure its digital transformation and energy transition. How do we anticipate the future supply chain for rare metals, monopolistic raw materials, and metals with very low reserves? ALCIMED, an innovation and new business consulting firm, has reviewed the criteria impacting the criticality assessment of a raw material.

Smartphone recycling: A sector of excellence in the making

French consumers change their mobile phones every other year. These devices have significant impacts on the environment. Rather than keeping our old smartphones in our drawers, solutions exist to give old smartphones a second life to avoid keeping them in a drawer. Alcimed reviews how the smartphone valorization chain is gradually being implemented.

Oral delivery of macromolecules: Big Pharma keep searching for the Holy Grail

Representing 9 out of the top 10 income-generating products on the market, biological drugs are now undoubtedly the main growth driver for the pharmaceutical industry. Big Pharma are looking not only to expand their portfolio with new macromolecules, but also to differentiate by offering delivery routes less invasive than injection for their blockbuster products. Oral delivery, long considered to be the Holy Grail, has been investigated for that objective for several years. How do market players position themselves in this race? Alcimed, an innovation and new business consulting firm, explores past and present challenges of these developments.

The CAR-T cell revolution: The funding puzzle

With impressive results, particularly where conventional treatments have failed, CAR-T cells represent a real revolution in onco-hematology care. Two treatments are already available in the United States and are about to arrive in Europe. Alcimed, a consulting company specialized in innovation and the new businesses, has investigated this expensive therapy whose next challenge is undeniably its financing.

Alzheimer’s: towards new modalities of care

Alzheimer is the most common neurodegenerative disease and is a source of great concern within our society. Currently, patients suffering from the condition are routinely treated with four drugs (and their generics). However, since August 1st 2018, after being deemed ineffective by the High Authority of Health (HAS), these drugs are no longer reimbursed in France. This decision, unique on a European scale, raises the question about care management of the 900,000 patients concerned1. The non-medicinal care available now, provides better support for patients, but the situation highlights the increased need to accelerate research to develop new curative molecules.

Innovations in the soft drinks segment

ALCIMED, a consulting company specialised in innovation and the development of new businesses, is looking at the revival of innovation in the soft drinks sector.

5 key trends in managing respiratory diseases

With more than 200 million patients suffering from Chronic Obstructive Pulmonary Disease (COPD), 235 million asthmatics, and 8.7 million patients affected by tuberculosis, respiratory diseases are gaining ground worldwide. Given these numbers and the impact on patients' quality of life, manufacturers are looking for innovations that could improve patient care. Alcimed, a consulting company specialized in innovation and new businesses, looked into the 5 key trends that will define the future of respiratory disease management.

Observations and evolution prospects for the PAERPA program within the frame of PTAs implementation.

Since 2016, the French Ministry of Social Affairs and Health has been rolling out their PAERPA program in one pilot territory per region, aiming at improving care for the ageing population and preventing the loss of its autonomy. Alcimed has supported several territories in the implementation of this program, both on the formalization of management procedures and on more operational aspects, capitalizing on the results of innovative actions carried out in the first pilot territories. The firm is now sharing its insight on the conditions for a successful roll-out and on the prospects of the PAERPA program in the context of the PTAs (Territorial Support Platforms) implementation.

Gene-editing: What’s next after CRISPR Cas9?

Alcimed, an innovation and new business consulting firm, is committed to supporting the pharmaceutical industry in observing emerging technologies such as gene editing technologies CRISPR Cas9 and the following generations.

Hydrogen, vector of energy transition

Hydrogen, applied for the first time in the field of aerospace, particularly in the Apollo Program, is now invading our daily lives. The many initiatives around this promising energy vector and the creation of the International Hydrogen Council in 2017 (around the French groups Air Liquide, Alstom, Engie and Total) are clear signs that the hydrogen revolution is in motion. Its high energy efficiency and storage capacities position hydrogen as a substitute for fossil fuels and as an integrator of renewable energies.

Medically assisted procreation: What are the future challenges for ART and IVF centers in France?

In response to societal demands for the availability of vitrification of oocytes and access to Assisted Reproductive Technologies (ART) for all women, the French Government has initiated national discussions that could potentially lead to evolutions in the context of medically assisted reproduction in France. Beyond the related ethical issues, a different type of challenge is emerging for ART and IVF (In vitro fertilization) centers: how to organize themselves to meet the increasing demand? Alcimed, a consulting company specialized in innovation and new business perspectives looked into the key future challenges lying ahead of these centers.

Lightweight and flexible cells, a new horizon for solar energy!

Lightweight and flexible photovoltaic solutions are continuously being developed. Numerous projects are emerging, mainly due to increasing yields and falling prices. These technologies are opening the door to new applications which were otherwise inaccessible with heavy and rigid panels. ALCIMED, a consulting firm specialized in innovation and new businesses, reviewed this technological (r)evolution that is opening doors to a world of new photovoltaic applications!

Preventive biology: definition and challenges

Alcimed, a consulting company specialized in innovation and new businesses, provides an update on the on the definition and challenges of preventive biology. As an integral part of "anti-aging" medicine it brings together applications at the frontiers of medicine and early diagnosis, sometimes incorporating controversial practices.

Natural and organic cosmetics: 5 unusual plants to rejuvenate the skin

While the global cosmetics market is growing steadily with annual growth rates of around 3.5%, natural and organic cosmetics seem to be doing even better with a projected annual rate reaching 10%. Plants have become an essential beauty ally, inviting themselves into the formulations of our cosmetic products. But beyond plant products that we traditionally find in our cosmetic departments such as aloe vera, shea butter, or argan oil, relying on the latest advances in research in herbal medicine, today's products appreciate the unknown plants with amazing properties. Alcimed, a consulting company specialized in innovation and new businesses, offers insights into these plants and the benefits they bring.

How to develop professional applications for drones?

Alcimed, a consulting company specialized in innovation and the developement of new markets, is looking into the growing use of drones for professional applications and the obstacles ans levers for their development.

A psychologist on your wrist: the future of mental health

Alcimed, an innovation and new business consulting firm, works with the pharmaceutical and medical device industries, to leverage new technologies, partners, and trends for innovative products in mental health diagnosis. has been launched: spread the word!

Alcimed Singapore is part of the "Smart Health initiative", an initiative which aims to promote French expertise in the healthcare sector through a visible and integrated community of French healthcare actors in Singapore. The objective is to bring French actors to participate in projects of focus for Singapore: innovation in health via digital tools, the silver economy and at -home care, fight diabetes in the region, ... The platform which sum-up all this French expertise is now active and has been officially launched in June 2017 . Visit the website:

Alzheimer’s: Reaching the cure within this generation

Alcimed, an innovation and new business consulting firm, remains committed to supporting the pharmaceutical industry in untangling the complex web of difficulties behind curing Alzheimer’s, a disease with one of the highest drug clinical trial failure rates.

Alcimed is imagining the hospital of the future

With the emergence of new technologies, the ageing population and the increasing of chronic diseases, the hospital, as known today, will go through massive changes in the next twenty years. Alcimed imagines the three wings that might constitute the hospital of the future in 2035.

Treatment adherence: The most important unmet need in healthcare

Alcimed, an innovation and new business consulting firm, looks at the causes and consequences of non-adherence to medications and stresses the necessity to develop efficient solutions to what is arguably the most important unmet need across the entire healthcare ecosystem.

Reduction of added sugars in solid foods: New issue and technological challenge for food companies

With the aim of improving public health, many national and international bodies are asking companies to limit the sugar intake of adults and children, encouraging them to reduce the quantity of added sugar, not only in drinks but also in solid foods. Alcimed, consultants in innovation and development of new markets, analyses the ability of the food-processing industry to face up to this issue.

Open innovation or how to reinvent new forms of collaboration between start-ups and large groups

Open innovation, or the ability to innovate beyond one's usual boundaries, has gained in importance during the last 10 years with the deployment of digital tools. In particular, we see it represented today by various forms of partnerships between large groups and players in their ecosystems, especially with start-ups. For these 'win – win' partnerships to become sustainable, traditional working processes must be optimised.

Nutrition and public health: The strengthened role of the food processing industries in public health problems

The prevalence of conditions partly related to diet, such as obesity (the worldwide prevalence of which has doubled since 19801), but also diabetes, cardiovascular diseases, certain cancers, etc., is growing constantly. Facing this trend, the food Industry is increasingly involved in the search for solutions. Alcimed, consultants in innovation and development of new markets, is looking into the positioning of food industries against the public health issues link to nutrition.

Is 3D printing going to revolutionise the healthcare sector and its business model?

The technique of 3D printing has become an essential production process in the healthcare sector, where it enables unequalled customisation of the therapeutic arsenal. Alcimed, consultants in innovation and development of new markets, is considering the various applications of 3D printing in healthcare and the prospects that it offers for a profoundly-changing sector that could require the economic models in use today to be rethought.

Pioneers or followers, the industry players will all turn to the IIoT

The connected objects are more and more part of our daily lives: computers, mobile phones, but also watches, clothing and countless sensors for the home or the car. These technologies are changing the functioning of our society and our way of life. Originally associated to the consumer sphere, the Internet of Things (IoT) is more and more interesting for industrials.

Flying cars: Is it allowed to dream?

Zee. Aero, Kitty Hawk, Ehang, Terrafugia, and now Airbus: many players are rushing to the “flying cars” market. The concept is receiving an increasing support from the institutional, industrial and financial worlds. It is gaining in maturity, and some start-ups promise to take it to the market next year. However, it remains certain that this market will not take off before a long time.

Translational research: innovation accelerator in the pharmaceutical industry

In a relatively unproductive environment of the pharmaceutical industry, translational research offers prospects for privileged innovation and challenges the way research is currently organised. Alcimed, consultants in innovation and development of new markets, raises the issues of translational research and its impact on the development of new treatments for patients.

Crowdsourcing: issues and benefits for pharmaceutical R&D

To optimise the R&D expenditure and support growth, pharmaceutical companies must alter their strategies. They are resorting increasingly to external innovation and particularly crowdsourcing to enable them to maintain or supplement their product pipelines.